Condition 1: Mild Depression. Condition 2: Moderate depression. Condition 3: Obseity. Mild depressive episode Two or three of the above symptoms are usually present. The patient is usually distressed by these but will probably be able to continue with most activities. Moderate depressive episode Four or more of the above symptoms are usually present and the patient is likely to have great difficulty in continuing with ordinary activities. Obesity due to excess calories
Conditions
Interventions
Intervention 1: 6 mg melatonin capsules (two 3 mg capsules one hour before bedtime) for 12 weeks. Intervention 2: Two placebo capsules for 12 weeks.
Treatment - Drugs
Placebo
6 mg melatonin capsules (two 3 mg capsules one hour before bedtime) for 12 weeks
Two placebo capsules for 12 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age 18 to 50 years; females; Body Mass Index above 25; patients with mild (minor) depression based on semi- structured diagnostic interview by a psychiatrist; to sign a consent form Exclusion Criteria: Those who are taking antidepressants; severe (major) depression; psychotic depression or have suicidal thoughts; use of anti-inflammatory glucocorticoids, and steroids; those who take medicines to reduce appetite or weight; those with diabetes who are taking medications or insulin; those with heart disease or hypercholesterolemia who are taking medication (statins, fibrates, diuretics); those how are taking oral anti-inflammatory drugs corticosteroids or any drug that causes weight loss or gain; taking hormonal contraceptives; pregnancy and lactation; menopause; severe mental disorder; schizophrenia and bipolar; hypothyroidism; exercise professionals; allergic to fish (due to Omega-3 supplements); those with special diets such as the diets for kidney disorders.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: at baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: Standard scales Seca.;Body Mass Index. Timepoint: at baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: kg/(m)2.;Depression. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: Hamilton rating scale for depression. | — |
Secondary
| Measure | Time frame |
|---|---|
| Central fat mass. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining. Method of measurement: Bioelectrical impadance.;Side effects. Timepoint: At the last secsion. Method of measurement: Side effect questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed-Ali Mostafavi
Psychiatry Research Center
Outcome results
None listed